These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22554357)

  • 21. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
    Prieto M; Berenguer M; Rayón JM; Córdoba J; Argüello L; Carrasco D; García-Herola A; Olaso V; De Juan M; Gobernado M; Mir J; Berenguer J
    Hepatology; 1999 Jan; 29(1):250-6. PubMed ID: 9862874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intracellular ATP production in CD4+ T cells as a predictor for infection and allograft rejection in trough-level guided pediatric liver transplant recipients under calcineurin-inhibitor therapy.
    Schulz-Juergensen S; Burdelski MM; Oellerich M; Brandhorst G
    Ther Drug Monit; 2012 Feb; 34(1):4-10. PubMed ID: 22210096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between adenosine triphosphate within CD4(+) T lymphocytes and acute rejection after liver transplantation.
    Dong JY; Yin H; Li RD; Ding GS; Fu ZR; Wu YM; Wang ZX
    Clin Transplant; 2011; 25(3):E292-6. PubMed ID: 21470308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss.
    Bahra M; Neumann UP; Jacob D; Langrehr JM; Neuhaus P
    Transplant Proc; 2005 May; 37(4):1700-2. PubMed ID: 15919436
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing immunologic function through CD4 T-lymphocyte ahenosine triphosphate levels by ImmuKnow assay in Chinese patients following renal transplantation.
    Zhou H; Wu Z; Ma L; Wu W; Yang S; Wang Q; Yuan X; Wu L; Lin X; Tan J
    Transplant Proc; 2011 Sep; 43(7):2574-8. PubMed ID: 21911125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients.
    Jacob DA; Neumann UP; Bahra M; Klupp J; Puhl G; Neuhaus R; Langrehr JM
    Clin Transplant; 2006; 20(2):211-20. PubMed ID: 16640529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation.
    Negro F; Giostra E; Rubbia-Brandt L; Mentha G; Colucci G; Morel P; Quadri R; Perrin L; Hadengue A
    J Med Virol; 1998 Nov; 56(3):224-9. PubMed ID: 9783689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid.
    Assy N; Adams PC; Myers P; Simon V; Minuk GY; Wall W; Ghent CN
    Transplantation; 2007 Jun; 83(12):1571-6. PubMed ID: 17589339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of an immune cell function assay to differentiate rejection from infectious enteritis in pediatric intestinal transplant recipients.
    Wozniak LJ; Venick RS; Gordon Burroughs S; Ngo KD; Duffy JP; Farmer DG
    Clin Transplant; 2014 Feb; 28(2):229-35. PubMed ID: 24433466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B; Aranda Narváez JM; Santoyo Santoyo J; Fernández-Aguilar JL; Suárez Muñoz MA; González-Sánchez AJ; Pérez Daga JA; Ramírez Plaza CP; Carrasco Campos J; Jiménez Mazure C; Becerra Ortíz R
    Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized immune monitoring of cardiac transplant recipients by noninvasive longitudinal cellular immunity tests.
    Israeli M; Ben-Gal T; Yaari V; Valdman A; Matz I; Medalion B; Battler A; Sredni B; Kristt D; Klein T
    Transplantation; 2010 Apr; 89(8):968-76. PubMed ID: 20075792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monitoring cellular immune function of renal transplant recipients based on adenosine triphosphate (ATP) production by mitogen-induced CD4+ T helper cells.
    Naderi H; Pourmand G; Dehghani S; Nikoueinejad H; Jafari M; Tajik N
    Biomed Pharmacother; 2018 Nov; 107():1402-1409. PubMed ID: 30257356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up.
    Neumann UP; Berg T; Bahra M; Puhl G; Guckelberger O; Langrehr JM; Neuhaus P
    Transplantation; 2004 Jan; 77(2):226-31. PubMed ID: 14742986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Kashyap R; Kosmach-Park B; Smith A; Fung JJ; Reyes J
    Transplantation; 2003 Apr; 75(7):1020-5. PubMed ID: 12698091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A quantitative assessment model of T-cell immune function for predicting risks of infection and rejection during the early stage after liver transplantation.
    Li RD; Sun Z; Dong JY; Yin H; Guo WY; Fu ZR; Wang ZX
    Clin Transplant; 2013; 27(5):666-72. PubMed ID: 23914809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimization of immunosuppressive therapy based on a multiparametric mixed lymphocyte reaction assay reduces infectious complications and mortality in living donor liver transplant recipients.
    Tanaka Y; Tashiro H; Onoe T; Ide K; Ishiyama K; Ohdan H
    Transplant Proc; 2012 Mar; 44(2):555-9. PubMed ID: 22410068
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence.
    Tisone G; Orlando G; Cardillo A; Palmieri G; Manzia TM; Baiocchi L; Lionetti R; Anselmo A; Toti L; Angelico M
    J Hepatol; 2006 Apr; 44(4):702-9. PubMed ID: 16473433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome of immunosuppression withdrawal after liver transplantation.
    Girlanda R; Rela M; Williams R; O'Grady JG; Heaton ND
    Transplant Proc; 2005 May; 37(4):1708-9. PubMed ID: 15919439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cell mediated immunity (CMI) and post transplant viral infections--role of a functional immune assay to titrate immunosuppression.
    Gautam A; Fischer SA; Yango AF; Gohh RY; Morrissey PE; Monaco AP
    Int Immunopharmacol; 2006 Dec; 6(13-14):2023-6. PubMed ID: 17161357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function.
    Emre S; Gondolesi G; Polat K; Ben-Haim M; Artis T; Fishbein TM; Sheiner PA; Kim-Schluger L; Schwartz ME; Miller CM
    Liver Transpl; 2001 Mar; 7(3):220-5. PubMed ID: 11244163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.